Litigation Details for FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)
✉ Email this page to a colleague
FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-05-29 |
| Court | District Court, D. New Jersey | Date Terminated | 2017-12-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Kevin McNulty |
| Jury Demand | Defendant | Referred To | Michael A. Hammer |
| Parties | MAIA PHARMACEUTICALS, INC. | ||
| Patents | 9,006,289; 9,168,238; 9,168,239 | ||
| Attorneys | CHRISTINA LYNN SAVERIANO | ||
| Firms | Knobbe Martens Olson & Bear LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for FRESENIUS KABI USA, LLC v. FERA PHARMACEUTICALS, LLC (D.N.J. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2016-09-20 | 327 | harma”).’ The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent” … — “289 Patent” United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. …of the 4 (See, e.g., ‘289 Patent Claim 1; ‘238 Patent Claim 1; ‘239 Patent buffer. …’s construction of key patent terms following a Markman hearing. This patent infringement case is brough…PageID: 7183 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). | External link to document | |
| 2016-09-20 | 328 | is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238…253- 4)). “‘289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). All three describe formulations of levothyroxine…2). “238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3). | External link to document | |
| 2016-09-23 | 333 | is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238…253- 4)). “289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”). All three describe formulations of levothyroxine…2). “238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3). | External link to document | |
| 2017-05-19 | 422 | three of its patents: Patent Nos. 9,006,289 (“the ‘289 patent”), 9,168,238 (“the ‘238 patent”), and the …the 9,168,239 (“the ‘239 patent”). All three patents describe formulations of levothyroxine, a hormone produced…by fraudulently obtaining the patents-in-suit and bringing sham patent litigation against it and other…Fresenius duped the patent examiner into granting Fresenius the ‘289, ‘238 and ‘239 patents through fraudulent…defendant (i.e., a non-patent holder) who filed a collateral proceeding at the Patent Office, such as an | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
